Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Abramson JS, Johnston PB, Kamdar M, Ibrahimi S, Izutsu K, Arnason J, Glass B, Mutsaers P, Lunning M, Braverman J, Liu FF, Crotta A, Montheard S, Previtali A, Guo S, Shi L, Solomon SR. Abramson JS, et al. Among authors: ibrahimi s. Blood Adv. 2022 Dec 13;6(23):5969-5979. doi: 10.1182/bloodadvances.2022008106. Blood Adv. 2022. PMID: 36149968 Free PMC article. Clinical Trial.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators. Kamdar M, et al. Among authors: ibrahimi s. Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6. Lancet. 2022. PMID: 35717989 Clinical Trial.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M. Abramson JS, et al. Among authors: ibrahimi s. Future Oncol. 2024 Mar 28. doi: 10.2217/fon-2023-0898. Online ahead of print. Future Oncol. 2024. PMID: 38547003 Free article. Review.
Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center.
Borogovac A, Keruakous A, Bycko M, Holter Chakrabarty J, Ibrahimi S, Khawandanah M, Selby GB, Yuen C, Schmidt S, Autry MT, Al-Juhaishi T, Wieduwilt MJ, Asch AS. Borogovac A, et al. Among authors: ibrahimi s. Bone Marrow Transplant. 2022 Jun;57(6):1025-1027. doi: 10.1038/s41409-022-01664-z. Epub 2022 Apr 11. Bone Marrow Transplant. 2022. PMID: 35411106 Free PMC article. No abstract available.
Extranodal Marginal Zone Lymphoma of the Central Nervous System.
Ayanambakkam A, Ibrahimi S, Bilal K, Cherry MA. Ayanambakkam A, et al. Among authors: ibrahimi s. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):34-37.e8. doi: 10.1016/j.clml.2017.09.012. Epub 2017 Sep 23. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29103980 Review.
Harnessing the PD-1 Pathway in Myelodysplastic Syndrome.
Mukherjee S, Ibrahimi S, Aljumaily R, Cherry M. Mukherjee S, et al. Among authors: ibrahimi s. Am J Ther. 2018 Nov/Dec;25(6):e711-e712. doi: 10.1097/MJT.0000000000000728. Am J Ther. 2018. PMID: 29394170 No abstract available.
100 results